Neo-Fradin Side Effects
Generic Name: neomycin
Note: This page contains side effects data for the generic drug neomycin. It is possible that some of the dosage forms included below may not apply to the brand name Neo-Fradin.
It is possible that some side effects of Neo-Fradin may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to neomycin: oral solution, oral tablet
As well as its needed effects, neomycin (the active ingredient contained in Neo-Fradin) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking neomycin, check with your doctor immediately:Rare
- Any loss of hearing
- difficulty in breathing
- greatly decreased frequency of urination or amount of urine
- increased amount of gas
- increased thirst
- light-colored, frothy, fatty-appearing stools
- ringing or buzzing or a feeling of fullness in the ears
- skin rash
Some neomycin side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
- Irritation or soreness of the mouth or rectal area
- nausea or vomiting
For Healthcare Professionals
Applies to neomycin: compounding powder, oral solution, oral tablet
Since oral neomycin (the active ingredient contained in Neo-Fradin) is absorbed systemically after oral administration, its use may result in nephrotoxicity, neurotoxicity and/or ototoxicity, even at recommended doses and in patients with normal renal function.
The major renal side effect of oral neomycin (the active ingredient contained in Neo-Fradin) is nephrotoxicity, which has occurred even at recommended doses and in patients with normal renal function.
Early signs of nephropathy include mild proteinuria, sloughing of renal tubular epithelial cells, formation of cellular casts, and decreases in creatinine clearance. Often there is a high output renal failure where daily urine volume may appear unchanged until significant increases in serum creatinine and BUN levels occur.
Neomycin damages renal tubules by causing tubular epithelial cell necrosis. It is considered the most nephrotoxic aminoglycoside.
Early symptoms of neomycin-induced auditory toxicity may manifest as high tone hearing loss, tinnitus, or a feeling of fullness in the ear, or its onset may be asymptomatic. If ototoxicity occurs, the onset of hearing loss is between several days to 6 weeks after therapy begins; however, it may not occur for months or years after neomycin (the active ingredient contained in Neo-Fradin) has been discontinued. Symptoms of vestibulotoxicity may include tinnitus, vertigo and ataxia.
Neomycin is considered more ototoxic than vestibulotoxic. It progressively accumulates in the inner ear and which leads to sensory hair cell loss in the in the cochlea and damage to the stria vascularis. In an animal study, neomycin was found to be more ototoxic than gentamicin, kanamycin and dihydrostreptomycin.
One case report series describes 5 cases of hearing impairment associated with long-term oral neomycin therapy for hepatic encephalopathy. Doses ranged from 2 to 12 g/day and were administered for 8 to 28 months; in 2 cases paromomycin was also administered. Renal failure did not occur.
Nervous system side effects associated with oral neomycin therapy have included neuromuscular blockade, respiratory paralysis, and eighth cranial nerve damage with hearing loss, even at recommended doses and in patients with normal renal function. Symptoms of neurotoxicity include numbness, tingling, muscle twitching, and convulsions.
Oral neomycin (the active ingredient contained in Neo-Fradin) therapy may result in overgrowth of nonsusceptible organisms, especially fungi.
A case of fatal Candida albicans pyelonephritis and septicemia following preoperative bowel preparation with oral neomycin and bacitracin has been reported.
Gastrointestinal side effects most commonly include nausea, vomiting and diarrhea. Clostridium difficile colitis has also been reported with oral neomycin (the active ingredient contained in Neo-Fradin) therapy.
More about Neo-Fradin (neomycin)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.